Rubicon's profit doubles, but growth is outpacing its own factories
Q4 revenue rose 44% to ₹514 cr and profit surged 112%, but higher-cost contract manufacturing is squeezing margins until a new plant comes online in 2027.
— 1 earlier story on Rubicon Research Ltd. →What's new
- Q4 revenue increased 44% to ₹514 cr and net profit jumped 112% to ₹76.8 cr.
- Management reiterated 22-23% EBITDA margin guidance, but gross margins are under pressure.
- Pithampur facility ramp-up remains on track for early 2027 to restore in-house production.
Why this matters
Rubicon is growing faster than it can manufacture. The demand surge has forced it to use expensive outsourced production, which is eating into gross margins. The company's fix—its own Pithampur plant—is still 18 months away. Maintaining the 22-23% EBITDA margin target will depend entirely on pricing discipline and product mix.
What we're watching
- The timeline for Pithampur's regulatory clearance and its impact on gross margins.
- How the Arinna Lifesciences acquisition translates into a higher-margin CNS portfolio.
- Whether outsourced manufacturing costs can be fully passed through in coming quarters.
The full read
Rubicon Research is growing faster than it can manufacture: Q4 revenue hit ₹514 crore, up 44%, and net profit more than doubled to ₹76.8 crore. The growth is currently funded by higher-cost outsourced manufacturing as the company uses contract manufacturers to meet demand that has exceeded internal capacity, squeezing gross margins. Management is sticking to its 22-23% EBITDA margin guidance, betting it can pass the costs on, but the real fix is the Pithampur facility, on track for an early-2027 ramp-up that will restore in-house production. Until then, margin pressure is the price of growth. The Arinna Lifesciences acquisition is a longer-term play to enter the higher-margin CNS market. A calculated trade-off. Near term, volume at the cost of margins.
Questions answered
- Why are gross margins under pressure despite strong revenue growth?
- Demand has exceeded Rubicon's internal manufacturing capacity, forcing the company to rely on higher-cost outsourced production. This is a temporary fix until its Pithampur facility is operational in early 2027.
- Is the 22-23% EBITDA margin guidance still credible?
- Management is maintaining the guidance. They believe they can offset higher manufacturing costs through pricing and a more favorable product mix in the coming quarters.
- What is the Arinna Lifesciences acquisition meant to do?
- It is a platform for Rubicon to enter the Central Nervous System (CNS) specialty market. The company aims to outperform general market growth in that segment by 2028.
- When does the Pithampur facility solve the margin problem?
- The facility is on schedule for a commercial ramp-up in early 2027. It will allow Rubicon to bring production back in-house, which is the primary lever for restoring gross margins.
Story so far
All notes on RUBICON →- 29 May 2026 · 9:03 PM IST Rubicon's profit doubles, but growth is outpacing its own factories
- 1d ago Rubicon Research's profit runs twice as fast as sales in FY26